The researchers developed two specific tweezers that bind and either disrupt biofilm formation or break existing biofilms
Antibiotic-resistant bacteria are a looming super threat – heralding a time when our drugs will no longer be effective against prevalent infections. Hospitals are already coping with treatment-resistant bacterial infections. Cognizant of the threat and thinking outside the box, Ben-Gurion University of the Negev (BGU) scientists and German and American colleagues have developed a pair of ‘molecular tweezers’ to destroy the biofilm that surrounds and protects virulent bacteria after entering the body.
The findings were published recently in Cell Chemical Biology.
The team, led by BGU’s Department of Chemistry Prof Raz Jelinek, and postdoc in his lab Dr Ravit Malishev, tested their molecular tweezers on the Staphylococcus aureus (Staph) bacteria. Staph infections have an estimated mortality rate in the US of over 25 per cent, and as much as 40 per cent for drug-resistant strains. The researchers developed two specific tweezers that bind and either disrupt biofilm formation or break existing biofilms.
“Our discovery prevents infection without building up antibiotic resistance. As such, it might even be preferable to construct treatments based on molecular tweezers rather than antibiotics,” says Prof Jelinek, who is also Ben-Gurion University’s Vice President of Research & Development and a member of the Ilse Katz Institute for Nanoscale Science and Technology. “Importantly, binding the tweezers to the biofilm disrupts its protective capabilities. In consequence, the bacterial pathogens become, on the one hand, much less virulent to the human body, and, on the other hand, more vulnerable to elimination by the immune system.”
Other researchers include: Orit Malka of BGU’s Department of Chemistry; Dr SofiyaKolusheva of the Ilse Katz Institute for Nanoscale Science and Technology at BGU; Nir Salinas and Prof Meytal Landau of the Department of Biology, Technion-Israel Institute of Technology, Landau is also a member of the European Molecular Biology Laboratory (EMBL), in Hamburg, Germany; James Gibson, Angela Bailey Eden, and Prof Chunyu Wang of the Center for Biotechnology and Interdisciplinary Studies, Department of Biological Sciences, Rensselaer Polytechnic Institute, Troy, New York; Joel Mieres-Perez, Yasser B Ruiz-Blanco, and Prof Elsa Sanchez-Garcia of the Department of Computational Biochemistry, the University of Duisburg-Essen in Essen, Germany; Prof Frank-Gerrit Klärner and Prof Thomas Schrader of the Faculty of Chemistry, University of Duisburg-Essen, Essen, Germany and Prof Gal Bitan of the Department of Neurology, David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California, Los Angeles.
This research was supported by the German Research Foundation, the Boehringer Ingelheim Foundation, and NIH/NIA grants R01AG050721 and RF1AG054000.
